PriceSensitive

China updates protocols on coronavirus which will benefit USCOM (ASX:UCM) products

ASX News, Health Care
ASX:UCM      MCAP $6.604M
14 February 2020 14:30 (AEST)

New recommendations to help treat children with the coronavirus have been released

They support the use of Uscom’s (UCM) health monitoring device, which tracks the severity of individual coronavirus cases

The recommendations are from the paediatric academies of Hubei Province and came soon after The China National Health Commission released a protocol on the detection and management of the virus.

These protocols all recommend haemodynamic (blood view) monitoring of severe and critically severe cases of coronavirus.

In the absence of effective vaccines, management of the virus includes support of the respiratory systems and heart.

USCOM 1A is a leading technology for measurement and monitoring the stroke volume and oxygen delivery.

The recommendation states that the treatment of severe cases should provide organ support in a timely manner. This involves ensuring enough oxygen is delivered.

USCOM 1A haemodynamic monitor was developed to optimise management of circulation in adults and children. Many of the monitors are installed in Chinese hospitals, mainly due to coronavirus.

The company said while many other devices may be used according to the guidance, but the process could involve catheters into the heart or arteries, which could be invasive.

“Events are moving very quickly in China and USCOM is committed to continuing its contribution to the improved diagnosis and treatment of all who acquire coronavirus, and for USCOM Chinese children are especially important,” Executive Chairman, Rob Phillips said.

Hubei has a population of approximately 59 million, with an estimated 12 million under 16 years of age.

USCOM is up 5.41 per cent on the market this afternoon, selling shares for 39¢ apiece at 2:14 pm AEDT.

Related News